Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of an HPV vaccine in healthy females aged 9-26 in China; status active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV vaccine

Snippet

Sponsor: Beijing Health Guard Biotechnology, Inc | Conditions: Human Papillomavirus Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING